The Scottish Medicines Consortium has endorsed NHS funding for four therapies that new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis. Pfizer’s Gemtuzumab ozogamicin was accepted for the treatment of acute myeloid leukaemia (AML), after being considered through the SMC’s Patient and Clinician Engagement (PACE) process. Current initial treatment for
NICE has recommended regular National Health Service funding for two more drugs from the old Cancer Drugs Fund – Pfizer’s Bosulif and Eli Lilly’s Alimta. The National Institute for Health and Care Excellence’s final guidance decision enables Alimta maintenance treatment to be available to a wider group of lung cancer patients. Bosulif is recommended for
New data showed Jardiance reduced the risk of new-onset or worsening kidney disease by 39% versus placebo when added to standard care in adults with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Lilly announced the findings at the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans early in the month.
Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payment of $787 million from
Eli Lilly and Company yesterday announced that they are conducting the first major international, prospective observational study intended to understand the real-world difficulties that people with type 2 diabetes face that result in preventing them from attainment their ultimate treatment goals. Many people with diabetes who take daily insulin resist a progression of insulin therapy
